PRTA vs ARTNA Comparison

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Artesian Resources Corp operates as a holding company based in the United States. Through its subsidiaries, it offers water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The Group distributes and sells water, including water for public and private fire protection, to residential, commercial, industrial, municipal, and utility customers. Additionally, it is involved in contract water and wastewater operations; offers wastewater services, and water, sewer, and internal Service Line Protection Plans. The Group operates its businesses mainly through one reportable segment, the Regulated Utility segment.